InMed Pharmaceuticals Inc. (NASDAQ: INM) released its financial results for the third quarter of the fiscal year 2023 which ended March 31, 2023, revealing sales of $1 million, an increase of 234% compared to $309,585 in Q3 2022.
Q3 FY 2023 Financial Highlights
Gross profit was $192,511 compared to $182,277 in Q3 FY 2022.
Net loss was $2 million compared to a loss of $3.5 million in Q3 FY 2022.
Cash and cash equivalents end of the period were $9.6 million
"The third quarter …